Cure My Disease

Don't miss your cure!

 Log in / Sign up

Radioactive tracer scan could replace invasive test for Hormone-Driven high blood pressure

NCT ID NCT07814105

Diagnosis Sponsor: Chinese University of Hong Kong Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 10, 2026 · Last updated Sep 11, 2026 · Updated 1 time

Summary

Researchers compare two ways to find which adrenal gland overproduces aldosterone in people with primary aldosteronism. One method uses a metomidate PET-CT scan with a radioactive tracer; the other uses adrenal vein sampling, an invasive catheter procedure. The trial measures how many participants achieve complete or partial clinical success after treatment guided by each approach.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a metomidate PET-CT scan using a radioactive tracer to find aldosterone-producing adrenal tissue
What this could lead to
If it works, this scan could offer a less invasive way to pinpoint which adrenal gland causes excess aldosterone, helping doctors choose surgery or medication.
What could go wrong
This is a small proof-of-concept study with 32 people, so results may not hold in larger groups. The scan uses a short-lived radioactive tracer and may not match the accuracy of adrenal vein sampling.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 32 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Sep 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of PA made based on Endocrine Society guidelines: * Participants should demonstrate a positive screening test for primary aldosteronism, defined as: * Paired measurement of renin and aldosterone demonstrating a raised aldosterone-to-renin ratio \>550 pmol/L/ng/mL/h AND * Suppressed renin \<=1ng/ml/h * AND participants should demonstrate autonomous aldosterone secretion following salt-loading confirmatory tests, defined as: * 1\) Non-suppressed aldosterone \>162pmol/L following seated saline infusion OR * 2\) raised 24-hour urine aldosterone \>38 nmol/d following oral salt loading test (17) * For participants with spontaneous hypokalemia with renin below detection level and plasma aldosterone \> 416 pmol/L(by LC-MS) at screening, the above confirmatory tests can be omitted due to high pre-test probability as proposed by latest guidelines (10). * Adrenal nodule on CT Exclusion Criteria: * Unable to give informed consent * Participants who neither agree to AVS nor MTO-PET * Patients who indicate they will not proceed to adrenalectomy * Patients contraindicated for mineralocorticoid receptor antagonists * Patients who are unable/unwilling or contraindicated for dexamethasone required for MTO-PET * Estimated GFR \< 30 ml/min/1.73m2 * Any illness or condition that is considered unfit for study by the investigators

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Primary aldosteronism are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hyperaldosteronism primary aldosteronism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Primary aldosteronism

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chinese University of Hong Kong

    Shatin, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.